OrganiGram Total Current Liabilities from 2010 to 2024
| OGI Stock | USD 1.52 0.01 0.66% |
Total Current Liabilities | First Reported 2011-09-30 | Previous Quarter 56 M | Current Value 47.9 M | Quarterly Volatility 24.7 M |
Check OrganiGram Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OrganiGram Holdings' main balance sheet or income statement drivers, such as Interest Expense of 303.5 K, Selling General Administrative of 59.1 M or Other Operating Expenses of 465.6 M, as well as many indicators such as Price To Sales Ratio of 2.86, Dividend Yield of 0.0 or PTB Ratio of 0.82. OrganiGram financial statements analysis is a perfect complement when working with OrganiGram Holdings Valuation or Volatility modules.
OrganiGram | Total Current Liabilities |
Latest OrganiGram Holdings' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of OrganiGram Holdings over the last few years. Total Current Liabilities is an item on OrganiGram Holdings balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of OrganiGram Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. OrganiGram Holdings' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OrganiGram Holdings' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
OrganiGram Total Current Liabilities Regression Statistics
| Arithmetic Mean | 16,223,087 | |
| Geometric Mean | 3,371,151 | |
| Coefficient Of Variation | 107.40 | |
| Mean Deviation | 14,323,377 | |
| Median | 11,250,000 | |
| Standard Deviation | 17,423,772 | |
| Sample Variance | 303.6T | |
| Range | 55.2M | |
| R-Value | 0.71 | |
| Mean Square Error | 160.4T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 2,780,781 | |
| Total Sum of Squares | 4250.2T |
OrganiGram Total Current Liabilities History
About OrganiGram Holdings Financial Statements
Investors use fundamental indicators, such as OrganiGram Holdings' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although OrganiGram Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 25.8 M | 18.3 M |
Currently Active Assets on Macroaxis
When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:Check out the analysis of OrganiGram Holdings Correlation against competitors. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OrganiGram Holdings. If investors know OrganiGram will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 1.835 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.55) |
The market value of OrganiGram Holdings is measured differently than its book value, which is the value of OrganiGram that is recorded on the company's balance sheet. Investors also form their own opinion of OrganiGram Holdings' value that differs from its market value or its book value, called intrinsic value, which is OrganiGram Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OrganiGram Holdings' market value can be influenced by many factors that don't directly affect OrganiGram Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OrganiGram Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if OrganiGram Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OrganiGram Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.